臨床検査67巻7号

2023年07月発行

今月の特集 造血器・リンパ系腫瘍のWHO分類　第5版

成熟B細胞腫瘍3—免疫不全症および免疫調節障害関連リンパ増殖症とリンパ腫/ホジキンリンパ腫/形質細胞腫瘍および異常蛋白を伴う他の疾患

著者： 市川聡¹

所属機関： ¹東北大学病院血液内科

ページ範囲：P.751 - P.756

Point

●免疫不全の概念の拡大とともに，免疫不全に関連して発症するリンパ増殖性疾患（LPD）は“免疫不全症および免疫調節障害関連リンパ増殖症（IDD関連LPD）”とカテゴリー分類され，病理診断名に原因ウイルスや臨床状況が付記されたかたちで記述される横断的な疾患概念となった．

●古典的Hodgkinリンパ腫（CHL）の分類には基本的に変更はない．結節性リンパ球優位型Hodgkinリンパ腫（NLPHL）は暫定的にHodgkinリンパ腫のくくりで分類されているが，将来的に変更がありうる．

●形質細胞腫瘍のカテゴリーでは，M蛋白沈着によって特徴付けられる病態の記述が拡大され，また，新たな疾患概念についての記述も追加された．

参考文献

1）Alaggio R, Amador C, Anagnostopoulos I, et al：The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia　36：1720-1748，2022

2）Jaffe ES, Harris NL, Stein H, et al：WHO Classification of Tumours of Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, p351, 2001

3）Swerdlow SH, Campo E, Harris NL, et al：WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, p439, 2008

4）Swerdlow SH, Campo E, Harris NL, et al：WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, Revised ed, IARC Press, Lyon, p585, 2017

5）Natkunam Y, Gratzinger D, de Jong D, et al：Immunodeficiency and Dysregulation: Report of the 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology. Am J Clin Pathol　147：124-128，2017

6）Natkunam Y, Gratzinger D, Chadburn A, et al：Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. Blood　132：1871-1878，2018

7）Attygalle AD, Cabeçadas J, Gaulard P, et al：Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward - report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology　64：171-199，2014

8）Naresh KN, Menasce LP, Shenjere P, et al：‘Precursors’ of classical Hodgkin lymphoma in samples of angioimmunoblastic T-cell lymphoma. Br J Haematol　141：124-126，2008

9）Shankar A, Hall GW, McKay P, et al：Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma - All StAGEs: A consensus-based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute. Br J Haematol　197：679-690，2022

10）Hartmann S, Eichenauer DA, Plütschow A, et al：The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood　122：4246-4292，2013

11）Rajkumar SV, Kyle RA, Therneau TM, et al：Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood　106：812-817，2005

12）Leung N, Bridoux F, Batuman V, et al：The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol　15：45-59，2019

13）Klomjit N, Leung N, Fervenza F, et al：Rate and Predictors of Finding Monoclonal Gammopathy of Renal Significance (MGRS) Lesions on Kidney Biopsy in Patients with Monoclonal Gammopathy. J Am Soc Nephrol　31：2400-2411，2020

14）Sykes DB, O'Connell C, Schroyens W：The TEMPI syndrome. Blood　135：1199-1203，2020

15）Sykes DB, Schroyens W, O'Connell C：The TEMPI syndrome--a novel multisystem disease. N Engl J Med　365：475-477，2011

16）Farooq U, Choudhary S, McLeod MP, et al：Adenopathy and Extensive Skin Patch Overlying a Plasmacytoma (AESOP) Syndrome. J Clin Aesthet Dermatol　5：25-27，2012

17）Rongioletti F, Romanelli P, Rebora A：Cutaneous mucinous angiomatosis as a presenting sign of bone plasmacytoma: a new case of (A)ESOP syndrome. J Am Acad Dermatol　55：909-910，2006

18）Boyle EM, Deshpande S, Tytarenko R, et al：The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun　12：293，2021

19）Maura F, Bolli N, Angelopoulos N, et al：Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun　10：3835，2019